泰達生物(08189.HK)一季度淨虧16.56萬元 同比收窄97.04%
格隆匯 5 月 10日丨泰達生物(08189.HK)公吿,截至2021年3月31日止三個月,集團實現綜合營業額為人民幣1.24億元,與去年同比增81.55%;公司股權擁有人應占虧損為人民幣16.56萬元,與去年同比減少97.04%;公司每股虧損人民幣0.009分,而去年同期每股虧損人民幣0.295分。
集團目前涉及兩大業務領域:一方面是生物複合肥業務,主要包括用於促進各種糧食及果蔬等作物均衡生長的多系列生物複合肥料產品。另一方面涉及養老及保健業務,主要包括全面佈局醫養結合的養老服務及運營管理業務,聚焦於失能失智、半失能半失智的剛需人羣,在全國範圍內開展養老機構(服務設施)運營管理、養老服務資源整合、養老服務管理督導與諮詢等相關養老服務業務;腦電波檢測業務方面,國內腦波檢測市場的拓展仍需要一定時間,腦波檢測業務發展較為緩慢,但集團依然在積極拓展客户並尋找新的合作伙伴,努力推進腦波檢測業務的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.